Search

Your search keyword '"Langbaum, Jessica B."' showing total 7 results
Start Over Author "Langbaum, Jessica B." Journal alzheimer's & dementia: translational research & clinical interventions
7 results on '"Langbaum, Jessica B."'

2. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease

Author

Lopez Lopez, Cristina, Tariot, Pierre N., Caputo, Angelika, Langbaum, Jessica B., Liu, Fonda, Riviere, Marie-Emmanuelle, Langlois, Carolyn, Rouzade-Dominguez, Marie-Laure, Zalesak, Martin, Hendrix, Suzanne, Thomas, Ronald G., Viglietta, Vissia, Lenz, Rob, Ryan, J. Michael, Graf, Ana, and Reiman, Eric M.

Published
2019
Full Text
View/download PDF

3. Measuring cognition and function in the preclinical stage of Alzheimer's disease

Author

Weintraub, Sandra, Carrillo, Maria C., Farias, Sarah Tomaszewski, Goldberg, Terry E., Hendrix, James A., Jaeger, Judith, Knopman, David S., Langbaum, Jessica B., Park, Denise C., Ropacki, Michael T., Sikkes, Sietske A.M., Welsh-Bohmer, Kathleen A., Bain, Lisa J., Brashear, Robert, Budur, Kumar, Graf, Ana, Martenyi, Ferenc, Storck, Marta Segardahl, and Randolph, Christopher

Published
2018
Full Text
View/download PDF

4. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort

Author

Tariot, Pierre N., Lopera, Francisco, Langbaum, Jessica B., Thomas, Ronald G., Hendrix, Suzanne, Schneider, Lon S., Rios-Romenets, Silvia, Giraldo, Margarita, Acosta, Natalia, Tobon, Carlos, Ramos, Claudia, Espinosa, Alejandro, Cho, William, Ward, Michael, Clayton, David, Friesenhahn, Michael, Mackey, Howard, Honigberg, Lee, Sanabria Bohorquez, Sandra, Chen, Kewei, Walsh, Trisha, Langlois, Carolyn, and Reiman, Eric M.

Published
2018
Full Text
View/download PDF

6. Alzheimer's Prevention Initiative Generation Program: Development of an APOEgenetic counseling and disclosure process in the context of clinical trials

Author

Langlois, Carolyn M., Bradbury, Angela, Wood, Elisabeth M., Roberts, J. Scott, Kim, Scott Y.H., Riviere, Marie-Emmanuelle, Liu, Fonda, Reiman, Eric M., Tariot, Pierre N., Karlawish, Jason, and Langbaum, Jessica B.

Abstract

As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E (APOE) results efficiently, safely, and effectively in the context of AD prevention trials.

Published
2019
Full Text
View/download PDF

7. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort

Author

Tariot, Pierre N., Lopera, Francisco, Langbaum, Jessica B., Thomas, Ronald G., Hendrix, Suzanne, Schneider, Lon S., Rios-Romenets, Silvia, Giraldo, Margarita, Acosta, Natalia, Tobon, Carlos, Ramos, Claudia, Espinosa, Alejandro, Cho, William, Ward, Michael, Clayton, David, Friesenhahn, Michael, Mackey, Howard, Honigberg, Lee, Sanabria Bohorquez, Sandra, Chen, Kewei, Walsh, Trisha, Langlois, Carolyn, and Reiman, Eric M.

Abstract

Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is, who have “preclinical” AD. Crenezumab is an antiamyloid monoclonal antibody that binds monomeric and aggregated forms of amyloid β, with highest affinity for oligomers; it is in development for early stages of sporadic AD and for ADAD.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results